Labetuzumab

Drug Profile

Labetuzumab

Alternative Names: Anti-CEA monoclonal antibody MN 14; CEA-Cide; hCEA; hMN-14; IMMU-100; IMMU-14; Monoclonal antibody MN-14

Latest Information Update: 19 Jan 2007

Price : $50

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Small cell lung cancer; Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; Colorectal cancer; Ovarian cancer

Most Recent Events

  • 05 Jun 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003) have been added to the Cancer pharmacodynamics section
  • 04 Nov 2002 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
  • 17 Aug 1999 CEA-Cide has Orphan Drug status for ovarian cancer in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top